Hydroxyethyl starch (HES) solutions for infusion: suspension of marketing authorisations due to continued use in contraindicated patient populations with increased risk of serious harm
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Active substance |
hydroxyethyl starch
|
| Regulatory outcome |
Suspension
|
| DHPC type |
Post-authorisation measure
|
| Referral name |
Hydroxyethyl starch (HES) containing medicinal products
|
| Dissemination date |
30/06/2022
|